NCT07094048
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Recruiting · Phase 4 · CHU de Quebec-Universite Laval · registry updated 2026-07-22
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Inclusion
- Multiple myeloma patient:
- ≥ 18 years old
- ≥ 1 prior lines of therapy
- Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
- On previous Ig support or not
Exclusion
- Less than 18 years old
- Pregancy or breastfeeding